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Available online 22 April 2016Background: Despite rapid reperfusion, mortality and morbidity in patients with an acute myocardial infarction
remain signiﬁcant. Therefore, novel pharmacological strategies to further limit ischemia–reperfusion (IR) injury
are warranted. In animal models of myocardial infarction, mineralocorticoid receptor antagonists potently limit
infarct size. In the current studywe aimed to translate these ﬁndings to the human situation and investigated for
the ﬁrst time in human myocardial tissue whether eplerenone limits IR-injury.
Methods: In 24 patients undergoing elective cardiac surgery, the right atrial appendage was harvested, and two
trabeculae were dissected from each appendage and suspended in an organ bath. We induced contraction by
electrical ﬁeld stimulation. Recovery of contractile force after a period of simulated ischemia and reperfusion
was used as well-validated endpoint of IR-injury. From each patients, the trabeculae were randomized to either
ischemic preconditioning (IP) or no IP (n= 12; positive control experiment) or to superfusion with eplerenone
(10 μM) or vehicle (n = 12) in a paired approach.
Results: IP improved recovery from19.9 (SEM3.3)% to 26.3 (SEM 4.3)% (p b 0.05). During vehicle and eplerenone
superfusion,mean recovery of contractile function after simulated ischemia and reperfusionwas 45.2 (SEM5.6)%
and 36.5 (SEM 4.1)% (p= 0.14).
Conclusion: Eplerenone does not limit IR-injury in human atrial tissue ex vivo. Our results are in sharp contrast to
preclinical studies demonstrating cardioprotective effects of mineralocorticoid receptor antagonist. With great
interest we await the results of the MINIMISE-STEMI study, in which the effect of MR antagonism onmyocardial
infarct size in humans is currently under investigation.








Rapid myocardial reperfusion is essential to limit infarct size in pa-
tients with a myocardial infarction. Paradoxically, reperfusion itself
can also aggravate injury (“reperfusion injury”) [1]. Therefore,mortality
and morbidity of these patients remain high, and novel strategies to re-
duce ischemia–reperfusion (IR) injury are needed. It has been suggested
that mineralocorticoid receptor (MR) antagonists might serve this goal,
since these drugs reducemorbidity andmortality in patients with heart
failure [2–4]. Indeed, direct cardioprotective effects of these drugs areability and freedom from bias of
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.
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adboud university medical cen-
land Ltd. This is an open access articlconsistently demonstrated in several murine models of myocardial in-
farction [5–10]. The acute administration of MR antagonists, either be-
fore the onset of ischemia or at the moment of reperfusion,
profoundly reduced infarct size (reviewed in [11]). In an elegant series
of experiments it has been shown that the cardioprotective effects of
theMR antagonists eplerenone and canrenoate depend on extracellular
adenosine formation [9]. Adenosine is an endogenous purine nucleo-
side, and stimulation of membrane-bound adenosine receptors induces
various effects, including attenuation of inﬂammation, vasodilation and
protection against IR [12].
Whether these cardioprotective effects of MR antagonists also hold
true in humans is yet unknown. In the current study, we aimed to trans-
late the preclinical ﬁndings to the human situation for the ﬁrst time and
test the hypothesis that the MR antagonist eplerenone limits IR-injury
in human myocardial tissue. We used the recovery of contractile func-
tion after a period of simulated IR in human atrial trabeculae as a
well-established model of myocardial IR-injury [13–15].e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Patients
Adult patients undergoing elective coronary artery bypass surgery
(CABG), valve surgery or aortic surgery, with extracorporeal circulation
were asked to participate. Exclusion criteria were atrial arrhythmias,
right ventricular failure, known atrial enlargement, the use ofmineralo-
corticoid receptor antagonists, and the use of oral antiarrhythmics
(except beta-blockers), sulfonylurea derivatives, dipyridamole, or the-
ophylline. Patients were asked to abstain from caffeine consumption
24 h before surgery, since caffeine is an effective adenosine receptor an-
tagonistwhich prevents the protective effects of ischemic precondition-
ing and might interfere with any protective effects of eplerenone [14].
All volunteers provided written informed consent before enrollment.
The study protocol was approved by the Institutional Review Board of
our center. The study was conducted in accordance with the Good
Clinical Practices and the Declaration of Helsinki and was prospectively
registered at ClinicalTrials.gov (NCT02118753).
2.2. Experimental design
We used the experimental set up as described previously [13,14].
Brieﬂy, the right atrial appendage was harvested by the cardiothoracic
surgeon before the introduction of the extracorporal circulation and
immediately placed in cold (4 °C) modiﬁed Tyrode's solution (NaCl
118.5 mmol/l, KCl 4.8 mmol/l, NaHCO3 24.8 mmol/l, KH2PO4
1.2 mmol/l, MgSO4 1.4 mmol/l, CaCl2 1.8 mmol/l, glucose 10.0 mmol/l,
and pyruvate 10.0 mmol/l), which was gassed with 95% oxygen and
5% CO2. Two atrial trabeculae were dissected, vertically suspended in
an organ bath, and linked to a force transducer. Each trabecula was
superfused with pre-oxygenated Tyrode's buffer. Electrical ﬁeld stimu-
lation was performed in unstretched condition at 1 Hz using platinum
ring electrodes placed on both sides of the trabeculae (pulse duration
60ms; pulse current 40mA). After 30min of stimulation at unstretched
conditions to allow recovery from transportation and preparation, tra-
beculaewere gradually stretched over 15min until maximal contractile
force was achieved. After 20 min of equilibration, a baseline recording
was performed during 10 min. Those trabeculae that failed to produce
at least 0.2 g of developed force at the end of baseline were excluded.
After 30 min of equilibration, the trabeculae were subjected to 90 min
of simulated ischemia, followed by105min of reperfusion. Simulated is-
chemiawas accomplished by superfusing the trabeculaewith substrate-
freemodiﬁed Tyrode's solution (7.0mMcholine chloride substituted for
glucose and pyruvate) and rapid pacing at 3 Hz. The superfusate was
pumped into an artiﬁcial lung ﬁlledwith 95% N2/5% CO2, which resulted
in a low pO2 of 10 to 20 mm Hg. For each patient, the trabeculae were
randomized to either an intervention or control to allow paired analysis
of the effects of the interventions.
First, as a positive control experiment, we studied the effect of ische-
mic preconditioning (IP) in 12 pairs of trabeculae, according to the ex-
perimental design we published previously [14]. Brieﬂy, immediately
after baseline recordings, the trabeculae of each patient (n = 12)
were randomly assigned to either a stimulus for IP or continued
superfusion with Tyrode's solution. IP was induced by 5min of simulat-
ed ischemia and 5 min of simulated reperfusion.
Subsequently, the trabeculae of 12 patients were randomly assigned
to superfusion with eplerenone (10 μM, kindly provided by Pﬁzer) or
vehicle (dimethyl sulfoxide, DMSO b 0.1%). Administration of
eplerenone started 10 min before simulated ischemia and continued
throughout the experiment.
2.3. Data recording and statistical analysis
The differences between the maximal tension during contraction
and the minimal tension during relaxation were averaged for every5 min (‘contractile force’). Recovery of contractile force in the last
10 min of reperfusion as a percentage of the last 10min of equilibration
was used as the primary endpoint.
For sample size calculation, we assumed a mean averaged percent-
age recovery of 18.7 ± 3.20%, and a test-to-test correlation coefﬁcient
of 0.5. A total of 12 subjects was required to detect a 37.5% change in av-
eraged percentage recovery, which is a relevant reduction of ischemia–
reperfusion injury, with a power of 80% at a signiﬁcance level of 0.05.
Data are presented as mean (SEM) and were analyzed with SPSS 22
forWindows.We assumed a one-sided (IP) and two-sided (eplerenone
versus vehicle) signiﬁcance level of 0.05. Datawere checked for normal-
ity and analyzed accordingly (Wilcoxon Rank test or Student's t-test).
3. Results
Of the 83 patients who initially signed their informed consent, suc-
cessful paired experiments in two trabeculae were performed in 24 pa-
tients. The reasons for exclusion of the patients, and the reasons for
drop-out are depicted in Fig. 1. The baseline characteristics of the pa-
tients are presented in Table 1.
In the positive control experiment, IP improved recovery from 19.9
(SEM 3.3)% to 26.3 (SEM4.3)% (p= 0.048), corroborating our previous
ﬁnding [6]. In the second set of experiments mean recovery of contrac-
tile function after reperfusionwas 45.2 (SEM 5.6)% and 36.5 (SEM4.1)%,
during vehicle and eplerenone superfusion, respectively (p = 0.14;
Wilcoxon Rank test). After exclusion of one outlier with a recovery of
98.6% in the control trabecula, the results remained unchanged (40.4
(SEM 3.1)% and 36.0 (SEM 4.4)% for vehicle and eplerenone respective-
ly; Fig. 2; p= 0.17 (Student's t-test)).
4. Discussion
Our study is the ﬁrst to investigate the direct effects of mineralocor-
ticoid receptor antagonism on ischemia–reperfusion injury in human
cardiac tissue. In contrast to various recent preclinical studies, in
which administration of MR antagonists consistently reduced myocar-
dial infarct size in animal models of myocardial infarction [11], we did
not observe any protective effect of eplerenone against IR-injury in
human myocardial tissue.
Postischemic recovery of contractile force of human atrial trabeculae
has been validated previously as a reliable and reproducible surrogate
model of humanmyocardial IR-injury. Ischemic preconditioning consis-
tently reduced IR-injury in thismodel in previous studies [13,14], which
was reproduced by the ﬁrst series of experiments in our current study.
Moreover, the protective effect of IP in thismodel is critically dependent
on adenosine receptor stimulation [14], opening of adenosine
triphosphate-dependent potassium (KATP) channels, and activation of
protein kinase C [13]. These mechanisms are of similar importance in
IP-mediated cardioprotection in animalmodels ofmyocardial infarction
using histological infarct size as endpoint of IR-injury [16]. These ﬁnd-
ings highlight that the mechanism of cardioprotection by IP is largely
similar in animal models of myocardial infarction and the model we
used in the current study.
In models of acute myocardial infarction in mice, rats, and rabbits,
acute administration of spironolactone, eplerenone, or canrenoate
profoundly limits infarct size [6–10]. Pathway analysis revealed that
increased extracellular adenosine formation and subsequent stimula-
tion of adenosine A2B receptors is critical for eplerenone-induced
cardioprotection [9]. Why do these consistent ﬁndings not translate to
a cardioprotective effect of eplerenone in our current study?
First, it is known that in general the external validity of animal stud-
ies is limited due to biological differences between animals andhumans.
This is illustrated by the fact that about 500 neuroprotective treatment
strategies improve outcome in animal models of ischemic stroke,
while only two have proven effective in patients [17]. In addition, we
used the recovery of contractile function as a marker for IR-injury.
Fig. 1. Progress of participants during the experiment.
Table 1
Baseline characteristics.
Variable (n) Setting 1 preconditioning
(n = 12)
Setting 2 eplerenone vs
control (n = 12)
Men 11 12




CABG + AVR 0 1
Aortic surgery 2 1
Cardiovascular risk factors
Hypertension 4 10
Diabetes mellitus 1 1
Current of former smoker 4 5
Positive family history 3 4
Dyslipidemia 7 4
BMI N 30 kg/m2 2 1
Medication
Aspirin 8 10
Beta blocker 10 9
ACE-inhibitor 4 5
ATII receptor antagonist 2 4
Ca-channel antagonist 1 5
Diuretic 1 5
Nitrate 1 1
Lipid lowering drug 9 4
Glucose lowering therapy 1 1
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is used as the primary endpoint. However, the protective effect of IP and
pivotal involvement of adenosine, PKC, and KATP-channels that has been
demonstrated in many animal models of myocardial infarction, could
previously be conﬁrmed in the atrial trabeculae model [13,14].
A second potential explanation relates to the presumed mechanism
of eplerenone-induced cardioprotection. In animals, increased
adenosine formation and receptor stimulation are critical for this effect.
We have recently demonstrated, however, that eplerenone does not in-
crease extracellular adenosine formation at relevant dosages in humans
in vivo [18]. This ﬁnding is consistent with the lack of a cardioprotective
effect in humans.
Thirdly, one could argue that the presence of the endogenous ligand
aldosterone is required for the protective effect of MR antagonists.
However, cardioprotective effects were also observed in hearts from
adrenalectomized rats [8] and in Langendorff perfusion models [11],
showing that the cardioprotective effect of MR antagonists in animals
is independent from the presence of aldosterone.
Finally, it is important to consider the dose and timing of administra-
tion of eplerenone. The concentration of eplerenone that we used
(10 μM), has been shown to limit IR-injury in a previous study [9] and
is approximately 6 times higher than the calculated (peak) plasma
levels in healthy adults after a one week treatment of eplerenone
50 mg bid [18]. Administration of eplerenone was started only 10 min
before simulated ischemia. However, the limited duration of exposure
to eplerenone does not explain its lack of beneﬁt in the current study,
Fig. 2. Contractile force during eplerenone versus placebo. The contractile force (difference betweenmaximal tension during contraction andminimal tension during relaxation) in paired
trabeculae (n = 11) during eplerenone exposure (10 μM) (ﬁlled circles) or control (open squares); exclusion of 1 outlier.
113T.N.A.(D.) van den Berg et al. / International Journal of Cardiology 216 (2016) 110–113since also in the animal studies, acute administration of MR antagonists
effectively reduced infarct size [11].
In summary, eplerenone does not limit IR-injury in human myocar-
dial tissue. These results are in sharp contrast to previous observations
in animal models of IR. Based on these promising preclinical data, a
large clinical trial was recently initiated to investigate whether MR an-
tagonist limit infarct size in patients with an acutemyocardial infarction
[19]. Therefore, patients with a STEMI will be randomized to an intrave-
nous bolus of canrenoate before coronary reperfusion, followedby three
months of oral spironolactone. With great interest we await the results
of this randomized controlled trial [19].
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